<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02939053</url>
  </required_header>
  <id_info>
    <org_study_id>IPD-SOZO-01</org_study_id>
    <nct_id>NCT02939053</nct_id>
  </id_info>
  <brief_title>Correlation of SOZO BIS Measures With CardioMEMS PA Pressure</brief_title>
  <official_title>Correlation of Bioimpedance Measurements From the SOZO Device With Pulmonary Arterial Pressure Measurements From the CardioMEMS HF System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ImpediMed Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Scripps Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ImpediMed Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to establish the degree to which change in the ratio of ECF to TBW measured&#xD;
      using the SOZO BIS device correlates with change in end-expiratory end-diastolic PAP measured&#xD;
      using the CardioMEMS HF System (St. Jude Medical).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, single-arm, observational, non-randomized clinical study that will&#xD;
      enroll patients with heart failure who have had a CardioMEMS™ device implanted to monitor&#xD;
      their diastolic pulmonary artery pressure. The study will recruit and enroll thirty&#xD;
      participants. Participants will be monitored daily at home for a period of 30 days. Each day,&#xD;
      the patient's diastolic pulmonary artery pressure will be measured by CardioMEMS™ and the&#xD;
      ImpediMed's BIS technology. Participant's weight will also be taken each day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2017</start_date>
  <completion_date type="Actual">June 25, 2019</completion_date>
  <primary_completion_date type="Actual">May 3, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the ratio of whole body ECF/TBW measured using the SOZO BIS device</measure>
    <time_frame>From baseline through study completion, an average of 30 days</time_frame>
    <description>Changes of body fluid levels in heart failure patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the ratio of thoracic ECF/TBW</measure>
    <time_frame>From baseline through study completion, an average of 30 days</time_frame>
    <description>Changes of thoracic fluid levels in heart failure patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the ratio of lower extremity ECF/TBW</measure>
    <time_frame>From baseline through study completion, an average of 30 days</time_frame>
    <description>Changes of lower limb fluid levels in heart failure patients</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3</enrollment>
  <condition>NYHA Class III Heart Failure</condition>
  <arm_group>
    <arm_group_label>Single-arm</arm_group_label>
    <description>All subjects enrolled will undergo measurements with the SOZO device daily for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SOZO</intervention_name>
    <description>The SOZO device is a bioimpedance spectroscopy device that measures bioimpedance parameters.</description>
    <arm_group_label>Single-arm</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Heart failure patients who have a cardioMEMS device&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older.&#xD;
&#xD;
          2. NYHA Class III HF.&#xD;
&#xD;
          3. Patient has undergone implantation of CardioMEMS HF System (St. Jude Medical).&#xD;
&#xD;
          4. Patient is characterized by at least one of the following:&#xD;
&#xD;
               -  CardioMEMS implanted within the previous 90 days&#xD;
&#xD;
               -  Received treatment with intravenous diuretics within the previous 30 days&#xD;
&#xD;
               -  Received dose escalation of oral diuretics at least twice within the previous 30&#xD;
                  days&#xD;
&#xD;
          5. Patient is able to sit upright for BIS measurements.&#xD;
&#xD;
          6. Patient provides written informed consent and authorization to use and disclose health&#xD;
             information.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient is enrolled in a concurrent interventional study of an experimental treatment&#xD;
             that may confound the results of this study, in the investigator's opinion.&#xD;
&#xD;
          2. Patient has a clinical condition that would not allow them to complete the study.&#xD;
&#xD;
          3. Patient is pregnant or lactating.&#xD;
&#xD;
          4. Patient has nephrotic syndrome or nephrosis.&#xD;
&#xD;
          5. Patient has estimated glomerular filtration rate (eGFR) &lt; 20 ml/min/1.73m2 or&#xD;
             end-stage renal disease requiring chronic dialysis.&#xD;
&#xD;
          6. Patient has been diagnosed with lymphedema.&#xD;
&#xD;
          7. Patient has chronic liver failure or cirrhosis.&#xD;
&#xD;
          8. Patient has a moderate or large pleural effusion as seen on chest X-ray.&#xD;
&#xD;
          9. Patient has been diagnosed with thrombophlebitis or deep vein thrombosis in arms or&#xD;
             legs in the past 90 days.&#xD;
&#xD;
         10. Patient has an implanted cardiac rhythm management device (pacemaker or implantable&#xD;
             cardioverter defibrillator).&#xD;
&#xD;
         11. Patient has an amputation of a limb.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Small, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lancaster General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2016</study_first_posted>
  <last_update_submitted>July 5, 2019</last_update_submitted>
  <last_update_submitted_qc>July 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioimpedance spectroscopy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a pilot study, no individual participant data will be made available.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

